Clik here to view.
JS InnoPharm Initiates Treatment With JSI-1187, a Selective ERK Inhibitor, in...
CHICAGO & SHANGHAI JS InnoPharm Ltd initiated the JSI-1187 plus dabrafenib combination dose-escalation phase of the Phase 1 study for patients with locally advanced or metastatic solid tumors...
View ArticleClik here to view.
Elpiscience to Present Its Novel Immunotherapies at Biotech Showcase™ during...
SHANGHAI & SUZHOU, China & GERMANTOWN, Md. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to discovering and developing...
View ArticleClik here to view.
PharmaEssentia Establishes a New Research and Development Facility in the...
TAIPEI,Taiwan PharmaEssentia Corporation, (TPEx:6446), a global biopharmaceutical innovator headquartered in Taiwan leveraging deep expertise and proven scientific principles to deliver new...
View ArticleClik here to view.
知临集团宣布发表其 PathsDx 技术的合作论文——PathsDx 技术是一种快速周转的低深度无偏倚宏基因组学测序工作流程，可在 Illumina...
NEW YORK & LONDON & PARIS 知临集团有限公司（纳斯达克股票代码：APM，巴黎泛欧证券交易所股票代码：APM）是一家临床阶段的生物制药公司，致力于解决肿瘤学、自身免疫性疾病和传染病领域未满足的医疗需求。知临集团很高兴地宣布其最新联合发布了一篇论文，评估Illumina 平台上的快速周转低深度无偏倚宏基因组测序工作流程。该项名为 PathsDx Test...
View ArticleClik here to view.
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx...
NEW YORK & LONDON & PARIS Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in...
View ArticleClik here to view.
InnoCare to Present Latest Clinical Data of Gunagratinib at the Upcoming 2023...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company will present the...
View ArticleClik here to view.
Clik here to view.
Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer...
SEOUL, South Korea Genexine (KOSDAQ: 095700), a publicly traded, clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of...
View ArticleClik here to view.
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of...
OSAKA, Japan & CAMBRIDGE, Mass. & PASADENA, Calif. Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced topline results from the Phase 2 SEQUOIA...
View ArticleClik here to view.
Clik here to view.
Vizgen Appoints Paul Rasmussen to Spearhead Recent Expansion of MERSCOPE™ in...
CAMBRIDGE, Mass. Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the appointment of industry veteran...
View ArticleClik here to view.
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China,...
OSAKA, Japan & CAMBRIDGE, Mass. Takeda (TSE:4502/NYSE:TAK) today announced that EXKIVITY® (mobocertinib) has been approved by the National Medical Products Administration (NMPA) of China for the...
View ArticleClik here to view.
Neutron Therapeutics Announces Successful Generation of a Neutron Beam for...
BOSTON Neutron Therapeutics (NT), a targeted radiation oncology therapy company developing a comprehensive clinical solution for Boron Neutron Capture Therapy (BNCT), today announced the successful...
View ArticleClik here to view.
New Company, Velsera, Represents Summa Equity’s Vision to Improve Global...
BOSTON & SAN FRANCISCO & STOCKHOLM New company Velsera was announced today at the J.P. Morgan Healthcare Conference in San Francisco, California. The vision for Velsera is supported by...
View ArticleClik here to view.
Mary Kay Inc. Company-Sponsored Foundations Give Millions Supporting Women’s...
DALLAS Throughout 2022, iconic beauty brand Mary Kay—along with its company-sponsored foundations—gave more than 3 million dollars to support women’s causes around the world. This press release...
View ArticleClik here to view.
武田的EXKIVITY® (mobocertinib)获得中国国家药监局批准，成为首个及唯一一个治疗EGFR外显子20插入的非小细胞癌患者的疗法
日本大阪和马萨诸塞州剑桥 (美国商业资讯)–武田(Takeda, TSE:4502/NYSE:TAK)今天宣布，EXKIVITY®...
View ArticleClik here to view.
ニュートロン・セラピューティクスが日本の湘南鎌倉総合病院でBNCT用中性子ビームの発生に成功したと発表
ボストン （ビジネスワイヤ） — ホウ素中性子捕捉療法（BNCT）の包括的な臨床ソリューションを開発している標的放射線がん療法企業のニュートロン・セラピューティクス（NT）は本日、標的材に対する業界有数の陽子線電流37mAでの陽子ビーム生成と、神奈川県の湘南鎌倉総合病院（SKGH）におけるnuBeam®システムでの最初の中性子ビーム生成に成功したと発表しました。...
View ArticleClik here to view.
玫琳凯公司赞助的基金会捐赠数百万美元以支持世界各地的女性事业
达拉斯 (美国商业资讯)–整个2022年，标志性美容品牌玫琳凯及其公司赞助的基金会捐赠了超过300万美元，用于支持世界各地的女性事业。 本新闻稿包含多媒体。此处查看新闻稿全文： https://www.businesswire.com/news/home/20230112005766/zh-CN/ Female entrepreneurs in Chuxiong, Yunnan...
View ArticleClik here to view.
メアリー・ケイの企業財団が世界各国で女性の福利の支援に向けて数百万ドルを寄付
ダラス （ビジネスワイヤ） — 象徴的な美容ブランドのメアリー・ケイは、同社が資金提供する財団と共に2022年全体で300万ドル以上を世界各国で女性の福利の支援のために寄付しました。 本プレスリリースではマルチメディアを使用しています。リリースの全文はこちらをご覧ください。：https://www.businesswire.com/news/home/20230112005768/ja/...
View ArticleClik here to view.
武田薬品のEXKIVITY®（モボセルチニブ）が中国NMPAより承認を取得し、EGFRエクソン20挿入変異陽性NSCLC患者に対する初にして唯一の治療薬となる
大阪 & 米マサチューセッツ州ケンブリッジ （ビジネスワイヤ） —...
View Article